Studie - Cancer Cachexia – Pipeline Review, H1 2012
Global Markets Direct
5 / 2012
75 Seiten
| Typ: | Studie |
| Sprache: | Englisch |
| Regionen: | Europa, Asien / Pazifik, Mittlerer Osten / Afrika, Nordamerika / USA, Australien, Mittel- / Südamerika |
| Verfügbarkeit: | verfügbar |
Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:
Cancer Cachexia — Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Cancer Cachexia - Pipeline Review, H1 2012', provides an overview of the Cancer Cachexia therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia. 'Cancer Cachexia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Cancer Cachexia.
- A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Cancer Cachexia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Cancer Cachexia - Pipeline Review, H1 2012', provides an overview of the Cancer Cachexia therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia. 'Cancer Cachexia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Cancer Cachexia.
- A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Cancer Cachexia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cancer Cachexia Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Cancer Cachexia 9
Cancer Cachexia Therapeutics under Development by Companies 11
Cancer Cachexia Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Cancer Cachexia Therapeutics — Products under Development by Companies 18
Cancer Cachexia Therapeutics — Products under Investigation by Universities/Institutes 19
Companies Involved in Cancer Cachexia Therapeutics Development 20
Eli Lilly and Company 20
Inovio Biomedical Corporation 21
BioLineRx, Ltd. 22
AEterna Zentaris Inc. 23
Helsinn Healthcare S.A. 24
Alder Biopharmaceuticals Inc. 25
Elixir Pharmaceuticals, Inc. 26
Vicus Therapeutics, LLC 27
OHR Pharmaceutical Inc. 28
Acacia Pharma Ltd. 29
Cancer Cachexia — Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
AEZS-130 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ALD-518 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
EX-1314 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VGX-3200 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Ghrelin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Enbrel - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Anamorelin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
APD209 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BL-6020 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
VT-122 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
OHR/AVR118 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
VT-122 + Nexavar - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MT-102 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Revlimid - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
LY2495655 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Drug For Cancer Cachexia - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Cancer Cachexia Therapeutics — Drug Profile Updates 58
Cancer Cachexia Therapeutics — Discontinued Products 64
Cancer Cachexia Therapeutics - Dormant Products 65
Cancer Cachexia — Product Development Milestones 66
Featured News & Press Releases 66
Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130 66
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 66
Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study 67
Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia 68
May 17, 2011: Ohr Pharmaceutical Receives Canadian Composition-of-Matter Patent For OHR/AVR118 69
Mar 17, 2011: PsiOxus Therapeutics Initiates Phase II Clinical Study Of Wasting Disease Therapeutic MT-102 69
Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics 70
Dec 14, 2010: Ohr Enrolls First Three Patients In Phase IIb Cachexia Trial 71
Nov 03, 2010: Ohr Pharmaceutical Inc. Announces $244,000 Grant Award 72
Dec 08, 2009: Ohr Reports New Interim Phase II Cachexia Clinical Data Of OHR/AVR118 72
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75
List of Tables
Number of Products Under Development for Cancer Cachexia, H1 2012 9
Products under Development for Cancer Cachexia — Comparative Analysis, H1 2012 10
Number of Products under Development by Companies, H1 2012 12
Number of Products under Investigation by Universities/Institutes, H1 2012 13
Comparative Analysis by Late Stage Development, H1 2012 14
Comparative Analysis by Mid Clinical Stage Development, H1 2012 15
Comparative Analysis by Early Clinical Stage Development, H1 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 17
Products under Development by Companies, H1 2012 18
Products under Investigation by Universities/Institutes, H1 2012 19
Eli Lilly and Company, H1 2012 20
Inovio Biomedical Corporation, H1 2012 21
BioLineRx, Ltd., H1 2012 22
AEterna Zentaris Inc., H1 2012 23
Helsinn Healthcare S.A., H1 2012 24
Alder Biopharmaceuticals Inc., H1 2012 25
Elixir Pharmaceuticals, Inc., H1 2012 26
Vicus Therapeutics, LLC, H1 2012 27
OHR Pharmaceutical Inc., H1 2012 28
Acacia Pharma Ltd., H1 2012 29
Assessment by Monotherapy Products, H1 2012 30
Assessment by Combination Products, H1 2012 31
Assessment by Stage and Route of Administration, H1 2012 33
Assessment by Stage and Molecule Type, H1 2012 35
Cancer Cachexia Therapeutics — Drug Profile Updates 58
Cancer Cachexia Therapeutics — Discontinued Products 64
Cancer Cachexia Therapeutics — Dormant Products 65
List of Figures
Number of Products under Development for Cancer Cachexia, H1 2012 9
Products under Development for Cancer Cachexia — Comparative Analysis, H1 2012 10
Products under Development by Companies, H1 2012 11
Products under Investigation by Universities/Institutes, H1 2012 13
Late Stage Products, H1 2012 14
Mid Clinical Stage Products, H1 2012 15
Early Clinical Stage Products, H1 2012 16
Discovery and Pre-Clinical Stage Products, H1 2012 17
Assessment by Monotherapy Products, H1 2012 30
Assessment by Combination Products, H1 2012 31
Assessment by Route of Administration, H1 2012 32
Assessment by Stage and Route of Administration, H1 2012 33
Assessment by Molecule Type, H1 2012 34
Assessment by Stage and Molecule Type, H1 2012 35
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cancer Cachexia Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Cancer Cachexia 9
Cancer Cachexia Therapeutics under Development by Companies 11
Cancer Cachexia Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Cancer Cachexia Therapeutics — Products under Development by Companies 18
Cancer Cachexia Therapeutics — Products under Investigation by Universities/Institutes 19
Companies Involved in Cancer Cachexia Therapeutics Development 20
Eli Lilly and Company 20
Inovio Biomedical Corporation 21
BioLineRx, Ltd. 22
AEterna Zentaris Inc. 23
Helsinn Healthcare S.A. 24
Alder Biopharmaceuticals Inc. 25
Elixir Pharmaceuticals, Inc. 26
Vicus Therapeutics, LLC 27
OHR Pharmaceutical Inc. 28
Acacia Pharma Ltd. 29
Cancer Cachexia — Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
AEZS-130 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ALD-518 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
EX-1314 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VGX-3200 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Ghrelin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Enbrel - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Anamorelin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
APD209 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BL-6020 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
VT-122 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
OHR/AVR118 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
VT-122 + Nexavar - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MT-102 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Revlimid - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
LY2495655 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Drug For Cancer Cachexia - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Cancer Cachexia Therapeutics — Drug Profile Updates 58
Cancer Cachexia Therapeutics — Discontinued Products 64
Cancer Cachexia Therapeutics - Dormant Products 65
Cancer Cachexia — Product Development Milestones 66
Featured News & Press Releases 66
Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130 66
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 66
Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study 67
Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia 68
May 17, 2011: Ohr Pharmaceutical Receives Canadian Composition-of-Matter Patent For OHR/AVR118 69
Mar 17, 2011: PsiOxus Therapeutics Initiates Phase II Clinical Study Of Wasting Disease Therapeutic MT-102 69
Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics 70
Dec 14, 2010: Ohr Enrolls First Three Patients In Phase IIb Cachexia Trial 71
Nov 03, 2010: Ohr Pharmaceutical Inc. Announces $244,000 Grant Award 72
Dec 08, 2009: Ohr Reports New Interim Phase II Cachexia Clinical Data Of OHR/AVR118 72
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75
List of Tables
Number of Products Under Development for Cancer Cachexia, H1 2012 9
Products under Development for Cancer Cachexia — Comparative Analysis, H1 2012 10
Number of Products under Development by Companies, H1 2012 12
Number of Products under Investigation by Universities/Institutes, H1 2012 13
Comparative Analysis by Late Stage Development, H1 2012 14
Comparative Analysis by Mid Clinical Stage Development, H1 2012 15
Comparative Analysis by Early Clinical Stage Development, H1 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 17
Products under Development by Companies, H1 2012 18
Products under Investigation by Universities/Institutes, H1 2012 19
Eli Lilly and Company, H1 2012 20
Inovio Biomedical Corporation, H1 2012 21
BioLineRx, Ltd., H1 2012 22
AEterna Zentaris Inc., H1 2012 23
Helsinn Healthcare S.A., H1 2012 24
Alder Biopharmaceuticals Inc., H1 2012 25
Elixir Pharmaceuticals, Inc., H1 2012 26
Vicus Therapeutics, LLC, H1 2012 27
OHR Pharmaceutical Inc., H1 2012 28
Acacia Pharma Ltd., H1 2012 29
Assessment by Monotherapy Products, H1 2012 30
Assessment by Combination Products, H1 2012 31
Assessment by Stage and Route of Administration, H1 2012 33
Assessment by Stage and Molecule Type, H1 2012 35
Cancer Cachexia Therapeutics — Drug Profile Updates 58
Cancer Cachexia Therapeutics — Discontinued Products 64
Cancer Cachexia Therapeutics — Dormant Products 65
List of Figures
Number of Products under Development for Cancer Cachexia, H1 2012 9
Products under Development for Cancer Cachexia — Comparative Analysis, H1 2012 10
Products under Development by Companies, H1 2012 11
Products under Investigation by Universities/Institutes, H1 2012 13
Late Stage Products, H1 2012 14
Mid Clinical Stage Products, H1 2012 15
Early Clinical Stage Products, H1 2012 16
Discovery and Pre-Clinical Stage Products, H1 2012 17
Assessment by Monotherapy Products, H1 2012 30
Assessment by Combination Products, H1 2012 31
Assessment by Route of Administration, H1 2012 32
Assessment by Stage and Route of Administration, H1 2012 33
Assessment by Molecule Type, H1 2012 34
Assessment by Stage and Molecule Type, H1 2012 35
- Blepharitis – Pipeline Review, H1 2013
- Bone Degeneration – Pipeline Review, H1 2013
- Cancer Cachexia – Pipeline Review, H1 2013
- Ebola and Marburg Infections – Pipeline Review, H1 2013
- Fibrosis – Pipeline Review, H1 2013
- Mumps – Pipeline Review, H1 2013
- Ragweed Allergy – Pipeline Review, H1 2013
- Secondary Progressive Multiple Sclerosis (SPMS) – Pipeline Review, H1 2013
- Muscle Atrophy – Pipeline Review, H1 2013
- Post Menopausal Osteoporosis – Pipeline Review, H1 2013
- Sarcopenia – Pipeline Review, H1 2013
- Cachexia – Pipeline Review, H1 2013
- Fracture – Pipeline Review, H1 2013
- Multiple Sclerosis – Pipeline Review, H1 2013
- Psoriatic Arthritis – Pipeline Review, H1 2013
- Renal Anemia – Pipeline Review, H1 2013
- Rheumatoid Arthritis – Pipeline Review, H1 2013
- Actonel (Osteoporosis) - Forecast and Market Analysis to 2022
- Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline Review, H1 2013
- Aprela (Osteoporosis) - Forecast and Market Analysis to 2022
*Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.
Hinweise: **The report can be shared by users within one office (one geographical location)
***Across Geographical locations (by the purchasing company only)
Für Sie protokollierte Studien / Marktanalysen:
zuletzt angesehene Studien:
Seite drucken
Seite empfehlen
Home | Werbung | Über marktforschung.de | AGB | Impressum | Sitemap | Suche © 2006 bis 2013 Alle Rechte bei marktforschung.de - Studie - Cancer Cachexia – Pipeline Review, H1 2012 - Marktdaten / Marktanalysen bei marktforschung.de